Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Madhu Chintala"'
Publikováno v:
TH Open, Vol 07, Iss 02, Pp e97-e104 (2023)
Abstract Background Factor XIa (FXIa) is an emerging therapeutic target, and FXIa inhibition is a promising mechanism to improve therapeutic index over current anticoagulants. Milvexian (BMS-986177/JNJ-70033093) is an oral small-molecule FXIa inhibi
Externí odkaz:
https://doaj.org/article/62a7421a50364701bd42a20a7eadc061
Autor:
Mihirbaran Mandal, Maria Madeira, Rupesh P. Amin, Alexei V. Buevich, Alan Cheng, Marc Labroli, Xiaoxiang Liu, John Acton, Barbara Pio, Andrea Basso, Harry Chobanian, Grace Dong, Jamie Dropinski, Yan Guo, Zhuyan Guo, Stan Kurowski, Walter Korfmacher, Sandra Lee, Dongfang Meng, Debra Ondeyka, Zhiqiang Yang, Rumin Zhang, Huijun Wei, Zhicai Wu, Fengqi Zhang, Gordon Wollenberg, Tesfaye Biftu, William J. Greenlee, Madhu Chintala, Milana Maletic, Zhaoning Zhu
Publikováno v:
Journal of Medicinal Chemistry. 65:5575-5592
Vorapaxar is an approved drug for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease. Subsequent to the discovery of Vorapaxar, medicinal chemistry efforts were co
Autor:
Vivaswath S. Ayyar, Pharavee Jaiprasart, Brian Geist, Madhu Chintala, Chyi-Hung Hsu, Zheng Huang Devine, Case Martin A, Anasuya Hazra, Weirong Wang
Publikováno v:
British Journal of Pharmacology. 178:3943-3958
BACKGROUND AND PURPOSE Antigen-binding fragment (Fab ) reversal agents were developed to reverse, in bleeding emergency, the long-acting anticoagulant effect of JNJ-64179375 (JNJ-9375), a monoclonal antibody that binds exosite-1 on thrombin. EXPERIME
Autor:
Guozhang Xu, Zhijie Liu, Xinkang Wang, Tianbao Lu, Renee L. DesJarlais, Tho Thieu, Jing Zhang, Zheng Huang Devine, Fuyong Du, Qiu Li, Cynthia M. Milligan, Paul Shaffer, Peder E. Cedervall, John C. Spurlino, Christopher F. Stratton, Beth Pietrak, Lawrence M. Szewczuk, Victoria Wong, Ruth A. Steele, Wouter Bruinzeel, Madhu Chintala, Jose Silva, Michael D. Gaul, Mark J. Macielag, Ravi Nargund
Publikováno v:
Journal of medicinal chemistry. 65(15)
Activated factor XI (FXIa) inhibitors are promising novel anticoagulants with low bleeding risk compared with current anticoagulants. The discovery of potent FXIa inhibitors with good oral bioavailability has been challenging. Herein, we describe our
Publikováno v:
Journal of Pharmacological Sciences, Vol 108, Iss 4, Pp 433-438 (2008)
Atherothrombotic disease is a leading public health problem. Although current antiplatelet agents, such as aspirin and adenosine diphosphate (ADP)-receptor antagonists, reduce the morbidity and mortality associated with atherothrombotic disease, the
Externí odkaz:
https://doaj.org/article/ec0479b8f3884cdc913e11a8b669840d
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 371:375-384
JNJ-64179375 (abbreviated as JNJ-9375) is a recombinant human immunoglobin G4 (IgG4) monoclonal antibody engineered to mimic an immunoglobin A (IgA) antibody that was identified in a patient who exhibited markedly prolonged clotting times but without
Autor:
Guo, Xinji, Kolpakov, Mikhail A., Hooshdaran, Bahman, Schappell, William, Wang, Tao, Eguchi, Satoru, Elliott, Katherine J., Tilley, Douglas G., Rao, A. Koneti, Andrade-Gordon, Patricia, Bunce, Matthew, Madhu, Chintala, Houser, Steven R., Sabri, Abdelkarim
Publikováno v:
In JACC: Basic to Translational Science January 2020 5(1):69-83
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Blood. 136:10-11
Background: FXIa inhibition is a promising antithrombotic drug target. BMS-986177/JNJ-70033093 (BMS-177/JNJ-3093) is a novel small molecular inhibitor of FXIa currently in Phase II clinical trials with the potential for reduced bleeding risk as compa
Publikováno v:
European Heart Journal. 39